

Table 2.6. Prevalence of HPV DNA in grade 3 vulvar intraepithelial neoplasia (VIN3) (9 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Toki <i>et al.</i> (1991), USA-Japan	ISH/SBH for HPV6, 11, 16 & 18	10 Basaloid VIN	N=4 (40%)	N=0 (0%)	N=0 (0%)	N=3 (75%)	N=1 (25%)	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
		2 Warty VIN	N=2 (100%)	N=0 (0%)	N=0 (0%)	N=2 (100%)	N=0 (0%)	N/A	N/A	N/A	N/A	
Park <i>et al.</i> (1991), New Zealand	ISH and PCR for HPV6, 11, 16 & 18	20 Warty VIN III	N=13 (65%)	N=0 (0%)	N=0 (0%)	N=13 (100%)	N=0 (0%)	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
		10 Basaloid VIN III	N=3 (30%)	N=0 (0%)	N=0 (0%)	N=3 (100%)	N=0 (0%)	N/A	N/A	N/A	N/A	
Hording <i>et al.</i> (1991), Denmark	E6/E7 for HPV16 type specific	19	N=15 (78.9%)	N=0 (0%)	N=0 (0%)	N=15 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	Frozen specimens.
Nuovo <i>et al.</i> (1991), USA	SBH and probes for HPV6, 11, 16, 18, 31, 33 & 35	22	N=13 (59.1%)	N=0 (0%)	N=0 (0%)	N=9 (69.2%)	N=0 (0%)	N=1 (7.7%)	N=0 (0%)	N=3 (23%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
Della Torre <i>et al.</i> (1992), Italy	SB (HPV6, 11, 16 & 18) and E5 (HPV6, 11) E7 (16 & 18)	7 VIN III	N=7 (100%)	N=0 (0%)	N=0 (0%)	N=7 (100%)	N=0 (0%)	N/A	N/A	N/A	N=0 (0%)	Frozen specimens.
		4 early ISSCC	N=4 (100%)			N=4 (100%)						
Hørding <i>et al.</i> (1993), Denmark	E6/E7 primers (6, 11, 16, 18, 33)	23	N=14 (60.9%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
Hørding <i>et al.</i> (1994), Denmark	E6/E7 primers (6, 11, 16, 18, 33)	13 Warty-type VINIII	N=17 (80.9%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples. VIN III adjacent to SCC.
		8 Basaloid-type VINIII										
Milde-Langosch <i>et al.</i> (1995), Germany	MY09/11 (HPV6/11, 16, 18, 31, 33, 35)	12	N=6 (50%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples. VIN samples adjacent to SCC.
van Beurden <i>et al.</i> (1995), The Netherlands	CPI and CPIG and sequencing. E6/E7	48 VIN III 22 Warty-type VIN III. 8 Basaloid-Type VIN III. 17 Mixed Type VIN III. 1 Differentiated VIN III.	N=44 (91.7%)	N/A	N/A	N=41 (93.2%)	N=0 (0%)	N=0 (0%)	N=1 (2.3%)	N=1 (2.3%) (HPV45) N=1 (2.3%) (HPVx)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. 2 patients were HIV positive. 2 of 48 VIN III HPV negative were b-globin negative.

Table 2.6. Prevalence of HPV DNA in grade 3 vulvar intraepithelial neoplasia (VIN3) (9 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Junge <i>et al.</i> (1995), Denmark	58 samples analyzed by E6/E7 primers (6/11, 16, 18, 31, 33); and 62 by ISH (6/11, 16/18, 31/33)	2 Pure Warty	ISH=24/62 (38.7%)	N=0 (0%)	N=0 (0%)	N=21 (87.5%)		N=3 (12.5%)		N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. Cases of severe dysplasia and carcinoma <i>in situ</i> .
		21 Warty + Basaloid 31 Basaloid + Warty 7 Warty + Basaloid + Simple 1 Simple	PCR= 51/58 (87.9%)	N=0 (0%)	N=0 (0%)	N=45 (88.2%)	N=0 (0%)	N=0 (0%)	N=6 (11.8%)	N=0 (0%)	N=0 (0%)	
Pilotti <i>et al.</i> (1995), Italy	ISH/SBH/PCR for HPV 6, 11, 16 & 18	6 VIN III	N=6 (100%)	N=0 (0%)	N=0 (0%)	N=6 (100%)	N=0 (0%)	N/A	N/A	N/A	N/A	Bouin or formalin-fixed paraffin-embedded tissue samples.
		7 <i>In situ</i> SCC	N=7 (100%)	N=0 (0%)	N=0 (0%)	N=7 (100%)	N=0 (0%)	N/A	N/A	N/A	N/A	
Petry <i>et al.</i> (1996), Germany	Dot-Blot hybridization and ISH	1 VIN I 1 VIN II 7 VIN III	Warty-Basaloid and Bowenoid Type N=1 (100%) N=1 (100%) N=6 (85.7%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Vulvar Scrapes. Immunocompromised women (HIV, Allograft recipients & other immunocompromised).
Trimble <i>et al.</i> (1996), USA	ISH for 6/11/16/18/31/33/35/42/43/44/45/51/52/56	54	N=48 (88.9%)	N=0 (0%)	N=0 (0%)	N=49/69 (71%) (includes 48 cases + 21 cases of Vulvar Cancer)	N=1/69 (1.45%) (includes 48 cases + 21 cases of Vulvar Cancer)	N=0 (0%)	N=0 (0%)	N=19 (27.5%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. Squamous hyperplasia (VIN2) and basaloid or warty VIN (VIN3) combined.
Kagie <i>et al.</i> (1997), The Netherlands	CPI and CPIIG and sequencing	33 VIN I	N=1 (3%)	N/A	N/A	N=1 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
		11 VIN II	N=3 (27.3%)			N=0 (0%)	N=0 (0%)	N=0 (0%)	N=2 (66%)	N=1 (33%) (HPV45)	N=0 (0%)	
		16 VIN III	N=8 (50%)			N=6 (75%)	N=0 (0%)	N=0 (0%)	N=1 (12.5%)	N=1 (12.5%) (HPV45)	N=0 (0%)	
Madeleine <i>et al.</i> (1997), USA	MY09/11 probes (6/11, 16, 18/45, 31/33/52) or RFLP	253	N=181 (71.5%)	N= 14 (7.7%)	N=156 (86.2%)	N=15 (8.3%) (HPV18/45)	N=15 (8.3%) (HPV31/33/52)	N=7 (3.9%) (HPVx)	N=21 (11.6%) (HPV16&Other) N=1 (0.5%) (HPV16&Other & Other) N=2 (1.1%) (HPV6/11&Other)	N=21 (11.6%) (HPV16&Other) N=1 (0.5%) (HPV16&Other & Other) N=2 (1.1%) (HPV6/11&Other)	Formalin-fixed paraffin-embedded tissue samples histological type not specified.	

Table 2.6. Prevalence of HPV DNA in grade 3 vulvar intraepithelial neoplasia (VIN3) (9 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions		Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
					6	11	16	18	31	33	Others (type)		
van Beurden <i>et al.</i> (1998), Netherlands	CPI and CPIIG and sequencing	27		N=27 (100%)	N/A	N/A	N=25 (92.6%)	N/A	N/A	N=1 (3.7%)	N=1 (3.7%) (HPV45)	N/A	Formalin-fixed paraffin-embedded tissue samples. Histological type not specified; patients with pre-existing, concomitant or subsequent cervical or vaginal neoplasm.
Kohlberger <i>et al.</i> (1998), Austria	GP5+/6+ without typing	2 VIN I 10 VIN II 16 VIN III	20 Basaloid-type VIN 8 Warty-type VIN	N=26 (92.8%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
Ngan <i>et al.</i> (1999), Hong Kong	L1-PCR for HPV16 & 18	17		N=12 (70.5%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
Lerma <i>et al.</i> (1999), Spain	VPHFast (450-bp-long fragment of L1 region from the open reading frame) for HPV16 and 18	6 Conventional 12 Warty/Basaloid		N=0 (0%) N=5 (41.7%)	N/A N/A	N/A N/A	N=0 (0%) N=5 (100%)	N/A N/A	N/A N/A	N/A N/A	N/A N/A	N/A N/A	Formalin-fixed paraffin-embedded tissue samples. Comparison of ISCC, VIN and LS.
Yang <i>et al.</i> (2000), USA	MY09/11 (6,11,16,18,33) ISH (6/11, 16/18, 31/33/51)	10 Simplex VIN. 12 samples (2 more new samples than the ones on MY09/11)		N=0 (0%) N=1 (8.3%)	N=0 (0%) N=0 (0%)	N=0 (0%) N=0 (0%)	N=0 (0%) N=0 (0%)	N=0 (0%) N=0 (0%)	N=0 (0%) N=0 (0%)	N=0 (0%) N=1 (100%), (HPV31 or 33 or 51)	N=0 (0%) N=0 (0%)	N=0 (0%) N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. Same samples analyzed with two different techniques.
Abdel-Hady <i>et al.</i> (2001), United Kingdom	GP5+/6+ and type-specific for 6/11, 16, 18, 31, 33	17 Warty 3 Basaloid 9 Warty-Basaloid 3 SCC		N=13 (76.5%) N=3 (100%) N=7 (77.8%) N=0 (0%)	N=3 (23%) N=2 (66.7%) N=0 (0%) N=0 (0%)		N=12 (92.3%) N=3 (100%) N=5 (71.4%) N=0 (0%)	N=0 (0%) N=0 (0%) N=0 (0%) N=0 (0%)	N=1 (7.7%) N=0 (0%) N=1 (14.3%) N=0 (0%)	N=0 (0%) N=0 (0%) N=2 (28.6%) (HPVx)	N=0 (0%) N=2 (66.7%) (HPV6/11&16) N=1 (14.3%) (HPV16&33)	N=3 (23%) (HPV6/11&16) N=1 (7.7%) (HPV 6/11&31)	Formalin-fixed paraffin-embedded tissue samples. cases were VIN2 or VIN3, predominantly (26/32) warty or mixed warty-basaloid type.

Table 2.6. Prevalence of HPV DNA in grade 3 vulvar intraepithelial neoplasia (VIN3) (9 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments	
				6	11	16	18	31	33	Others (type)			
Carter <i>et al.</i> (2001), USA	MY09/11 and RFLP; type-specific for 16, 18	181	N=165 (91.2%)	N/A	N/A	N=135 (81.8%)	N=12 (7.3%)	N=16 (9.7%) (HPV30/31/33/35/39)		N=13 (7.9%) (HPV6/45/52/54/58/66/72/73/x)	N=11 (6.7%)	Formalin-fixed paraffin-embedded tissue samples. carcinoma <i>in situ</i> . Patients with either a HPV16 and/or HPV18 serology result.	
Gasco <i>et al.</i> (2002), UK	MY09/11, CPI/IIG	4 VIN I	N=0 (0%)	N/A	N/A	N=0 (0%)	N/A	N/A	N/A	N/A	N/A	N/A	Snap frozen biopsies.
		6 VIN II	N=1 (16.7%)	N/A	N/A	N=1 (100%)	N/A	N/A	N/A	N/A	N/A	N/A	
		22 VIN III	N=11 (50%)	N/A	N/A	N=11 (100%)	N/A	N/A	N/A	N/A	N/A	N/A	
Baldwin <i>et al.</i> (2003), UK	GP5+/6+	11	N=11 (100%)	N=0 (0%)	N=0 (0%)	N=10 (90.9%)	N=0 (0%)	N=0 (0%)	N=1 (9.1%)	N=0 (0%)	N=0 (0%)	Snap frozen biopsies.	
Todd <i>et al.</i> (2004), UK	GP5/6 and type-specific for 16, 18, 31, 33	9 VIN III	N=8 (88.9%)	N/A	N/A	N=6 (75%)	N=0 (0%)	N=0 (0%)	N=2 (25%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. 77.8% of cases had prior history of CIN.	
Bryndorf <i>et al.</i> (2004), Denmark	SPF-PCR (LiPA), HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 74	1 VIN I	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
		1 VIN II	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	
		9 VIN III	N=9 (100%)	N=0 (0%)	N=0 (0%)	N=7 (77.8%)	N=0 (0%)	N=0 (0%)	N=2 (22.2%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	
Rufforny <i>et al.</i> (2005), USA	ISH. E6&E7 primers for HPV16	10 VIN I	N=1 (10%)	N/A	N/A	N=1 (100%)	N/A	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
		3 VIN II	N=2 (66.7%)			N=2 (100%)							
		21 VIN III	N=17 (80.9%)			N=17 (100%)							
Bonvicini <i>et al.</i> (2005), Italy	ISH/MY09/11	5 VIN II (4 Warty + 1 Warty+Basaloid)	N=4 (80%)	N=0 (0%)		N=4 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
		4 Warty VIN III	N=3 (75%)	N=0 (0%)		N=2 (66.7%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=1 (33.3%) (HPV35)	N=1 (33.3%)	
		5 Basaloid VIN III	N=3 (60%)	N=0 (0%)		N=2 (66.7%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=1 (33.3%) (HPV35)	N=1 (33.3%)	
		4 Warty+Basaloid VIN III	N=1 (25%)	N=0 (0%)		N=1 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	
		7 Keratinizing Differentiated VIN	N=0 (0%)	N=0 (0%)		N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	

Table 2.6. Prevalence of HPV DNA in grade 3 vulvar intraepithelial neoplasia (VIN3) (9 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Hampf <i>et al.</i> (2006), Germany	MY09/11, GP5+/GP6+ and type-specific for HPV6, 11, 16, 18, 31, 33, 35, 40, 42, 44, 45, 51, 52, 53, 55, 56, 58, 61, 66, 67, 68, 73, 74, 91, IS887/MM4 & HPV1A18	183 VINII/III	N=169 (92.3%)	N=8 (4.7%)		N=134 (79.3%)	N=5 (3%)	N=7 (4.14%)	N=18 (10.65%)	N=1 (0.6%) (HPVx)	N=22 (13%)	Formalin-fixed paraffin-embedded tissue samples.
van der Avoort <i>et al.</i> (2006), The Netherlands	SPF-PCR (LiPA), HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 74	5 Classic VIN I	N=2 (40%)	N=2 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. Depending on the stage of dysplasia, higher VIN lesions are often more positive for HPV DNA. 87% (13/15) of the hr-HPV+ classic VIN lesions expressed both p14ARF and p16INK4A.
		7 Classic VIN II	N=5 (71.4%)	N=2 (40%)		N=2 (40%)	N=1 (20%)	N=0 (0%)				
		17 Classic VIN III	N=12 (70.6%)	N=0 (0%)		N=10 (83.3%)	N=1 (8.3%)	N=1 (8.3%)				
		8 Differentiated VIN III	N=1 (12.5%)	N=0 (0%)		N=1 (100%)	N=0 (0%)	N=0 (0%)				
Goffin <i>et al.</i> (2006), Canada	HC-2 Digene cervical sampler. ISH for 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68	22 current VIN III	N=14 (63.6%)	N/A	N/A	N=11/19 (57.9%) High-Risk HPV DNA					N/A	Exfoliated Cells taken by swabs.
		30 past history VIN III (trated last 2 years)	N=10 (33.4%)									
Hillemanns <i>et al.</i> (2006), Germany	Hybrid Capture 2 HPV DNA assay. HPV low-risk 6, 11, 42, 43 and 44. HPV High-risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68	1 VIN I	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. A significant correlation of High-risk HPV DNA positivity was noted with multifocal VIN (P=0.016). Coexistent or previous neoplasia was identified in 16 (53.3%) of the 30 patients. HR HPV was found in 14 (87.5%) of these 16 patients. 13 patients had a history of CIN and 5 patients had a history of VAIN.
		4 VIN II	N=3 (75%)	N=1 (33.3%)		N=3 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=1 (33.3%) (HPV16&LR)	
		25 VIN III	N=22 (88%)	N=3 (13.6%)		N=20 (91%)	N=1 (4.5%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=1 (4.5%) (HPV16&LR) N=1 (4.5%) (HPV18&LR)	

Table 2.6. Prevalence of HPV DNA in grade 3 vulvar intraepithelial neoplasia (VIN3) (9 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Srodon <i>et al.</i> (2006), USA	PGMY and DDL SPF 10	33 VIN I	N=30 (90.1%)	N=9 (30%)	N=5 (16.7%)	N=2 (6.7%)	N=0 (0%)	N=1 (3.3%)	N=1 (3.3%)	N=3 (10%) (HPV68) N=2 (6.7%) (HPV51) N=2 (6.7%) (HPV58) N=2 (6.7%) (HPV59) N=1 (3.3%) (HPV52) N=1 (3.3%) (HPV53) N=1 (3.3%) (HPV66) N=11 (36.7%) (HPV32/40/44/54/61/70/72/84/91)	N=7 (23.3%)	Formalin-fixed paraffin-embedded tissue samples.
Srodon <i>et al.</i> (2006), USA	PGMY and DDL SPF 10	34 VIN III	N=34 (100%)	N=0 (0%)	N=1 (2.9%)	N=31 (91.2%)	N=2 (5.9%)	N=0 (0%)	N=1 (2.9%)	N=2 (5.9%) (HPV35) N=1 (2.9%) (HPV51) N=1 (2.9%) (HPV52) N=1 (2.9%) (HPV68)	N=4 (11.8%)	Formalin-fixed paraffin-embedded tissue samples.
van Seters <i>et al.</i> (2007), The Netherlands	GP5+/GP6+, and HPV Type specific for 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 & 68 and other 20 Low risk types	9 VIN I 11 VIN II 6 VIN III	N=1 (11.1%) N=4 (36.4%) N=3 (50%)	N=0 (0%) N=0 (0%) N=0 (0%)	N=0 (0%) N=0 (0%) N=0 (0%)	N=1 (100%) N=3 (75%) N=3 (100%)	N=0 (0%) N=0 (0%) N=0 (0%)	N=0 (0%) N=0 (0%) N=0 (0%)	N=0 (0%) N=1 (25%) (HPV59) N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. VIN cases with Liquefactive Necrosis without coexistent SCC.	

Table 2.6. Prevalence of HPV DNA in grade 3 vulvar intraepithelial neoplasia (VIN3) (9 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments	
				6	11	16	18	31	33	Others (type)			
Santos <i>et al</i> (2006), Spain	GP5+/GP6+ & SPF10; INNO-LIPA	7 Basaloid/Warty VIN III	N=7 (100%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
		31 Differentiated (simplex) VIN III	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	
Hampl <i>et al.</i> (2007), Germany	MY09/11, GP5+/GP6+ and type-specific for HPV6, 11, 16, 18, 31, 33, 35, 40, 42, 44, 45, 51, 52, 53, 55, 56, 58, 61, 66, 67, 68, 73, 74, 91, IS887/MM4 and HPV1A18	4 VIN I	N=3 (75%)	N=0 (0%)	N=0 (0%)	N=1 (33.3%)	N=0 (0%)	N=1 (33.3%)	N=0 (0%)	N=1 (33.3%)	N=1 (33.3%)	N=1 (33.3%)	Formalin-fixed paraffin-embedded tissue samples. 52 patients with multicentric preneoplastic lesions (anus, vulva, vagina and cervix).
		14 VIN II	N=12 (85.7)	N=1 (8.3%)	N=0 (0%)	N=8 (66.7%)	N=1 (8.3%)	N=1 (8.3%)	N=0 (0%)	N=1 (8.3%)	N=1 (8.3%)	N=1 (8.3%)	
Hampl <i>et al.</i> (2007) (contd)		36 VIN III	N=34 (94.4%)	N=1 (2.9%)	N=0 (0%)	N=25 (73.5%)	N=0 (0%)	N=3 (8.8%)	N=4 (11.76%)	N=1 (2.9%)	N=3 (8.8%)		

Table 2.6. Prevalence of HPV DNA in grade 3 vulvar intraepithelial neoplasia (VIN3) (9 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Skapa <i>et al.</i> (2007), Czech Republic	GP5+/GP6+	4 VIN I	N=4 (100%)	N=0 (0%)	N=0 (0%)	N=2 (50%)	N=0 (0%)	N=0 (0%)	N=1 (25%)	N=1 (25%) (HPV45)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
		12 VIN II	N=12 (100%)	N=1 (8.3%)	N=1 (8.3%)	N=6 (50%)	N=2 (16.7%)	N=0 (0%)	N=3 (25%)	N=2 (16.7%) (HPV43) N=1 (8.3%) (HPV42) N=1 (8.3%) (HPV56)	N=5 (41.7%)	
		66 VIN III	N=65 (98.5%)	N=0 (0%)	N=0 (0%)	N=54 (83%)	N=1 (1.5%)	N=0 (0%)	N=9 (13.8%)	N=2 (3%) (HPV45) N=1 (1.5%) (HPV59)	N=2 (3%)	
		12 Differentiated (simplex) VIN	N=1 (8.3%)	N=0 (0%)	N=0 (0%)	N=1 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	
van Seters <i>et al.</i> (2008), The Netherlands	GP5+/GP6+	52 VIN II-III	N=50 (96.2%)	N=0 (0%)	N=0 (0%)	N=41 (82%)	N=1 (2%)	N=0 (0%)	N=8 (16%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.

a. percentages given are percentages of HPV positives among all samples.

b. percentages given are percentages of HPV types among HPV positives cases.